ライフサイエンスコーパス: cure rate

1 (TCD(50), radiation dose yielding 50% tumor cure rate).

2 th mebendazole (P=0.02 for the comparison of cure rates).

3 stimulus was associated with a reduced mouse cure rate.

4 n they are macroadenomas with a low surgical cure rate.

5 Parathyroidectomy achieved a 98% cure rate.

6 Primary endpoint was day 28 cure rate.

7 d-stage HL have contributed to an increasing cure rate.

8 in the irradiation field, resulting in a low cure rate.

9 hes will probably lead to an increase in the cure rate.

10 d at enrollment, which means there was a 96% cure rate.

11 hree components that resulted in the highest cure rate.

12 rvival benefit remains high and tends to the cure rate.

13 peg-IFN/RBV was associated with a very high cure rate.

14 no significant improvement in recurrence and cure rates.

15 vedotin will hopefully further increase the cure rates.

16 ancer (TC) represents a malignancy with high cure rates.

17 ildren with cancer can achieve the same high cure rates.

18 ve rifampin to other antibiotics may improve cure rates.

19 current challenges to overcome for improved cure rates.

20 herapy or cystectomy, thus improving overall cure rates.

21 e was no evidence that split dosing enhanced cure rates.

22 hat to treat appropriate targets and improve cure rates.

23 us (HIV)-infected patients results in modest cure rates.

24 population and yields high local control and cure rates.

25 mation to further refine therapy and advance cure rates.

26 5 year follow-up while maintaining excellent cure rates.

27 are appropriate operations that achieve high cure rates.

28 s was well-tolerated but resulted in limited cure rates.

29 ncrease remission rates and potentially also cure rates.

30 The cure rate (16%) after complete CRS of colorectal periton

31 World, the combined placebo and cryotherapy cure rate (18%; 95% CI, 10%-31%) is likely to become the

32 Intention-to-treat analysis showed initial cure rates (2 months after treatment) of 22.2% (6 of 27)

33 the DNR control arm received high DNR doses (cure rate, 27.4% for IDA v 15.9% for DNR; P = .049).

34 for Vibramycin (95% CI for the difference in cure rates, -4.3% to 4.9%).

35 Splenectomy continues to provide the highest cure rate (60%-70% at 5+ years).

36 Both the immediate postoperative cure rate (65% vs. 44%; P = 0.010) and long-term cure ra

37 Patients infected with BI had lower cure rates (86.6%; 214 of 247) than those infected with

38 rative success (93.9 vs 95.6%, P = 0.073) or cure rates (96.2% vs 97.7%, P = 0.291) between nonlocali

39 ents, there was no significant difference in cure rates (97.8 vs 97.4%, P = 0.760) between nonlocaliz

40 ications (4 vs 0 complications; P = .32), or cure rates (98.6% vs 96.6%; P = .50).

41 ctomy is associated with improvements in the cure rate (99.4%) and the complication rate (1.45%) comp

42 In conclusion, the rapid cure rate achieved with these combinations is largely di

43 The cure rate after parathyroidectomy was 98%.

44 The cure rate after parathyroidectomy was 98.2%.

45 8 to compare patterns of disease relapse and cure rates after craniospinal radiotherapy, reduced-volu

46 the same time period, evaluated biochemical cure rates after systematic lymph node dissection.

47 py in the intention-to-treat population, the cure rate among participants in the clindamycin group wa

48 famethoxazole treatment resulted in a higher cure rate among patients with a drained cutaneous absces

49 cutaneous leishmaniasis (CL), and different cure rates among New World CL have been obtained dependi

50 metastatic colorectal cancer and increasing cure rates among those with resectable disease.

51 ice at 25 mg/kg for 30 days cures, with 100% cure rate and 100% survival, the acute and chronic T. cr

52 new therapies are needed that offer a higher cure rate and a better safety profile, with convenience

53 e approach to this disease, providing a high cure rate and acceptable morbidity compared to non-PD re

54 a safe approach associated with an excellent cure rate and an overall low treatment burden despite a

55 was determined by means of assessment of the cure rate and egg-reduction rate.

56 Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with

57 h acute promyelocytic leukaemia, with a high cure rate and less relapse than, and survival not differ

58 Patients with cancer had a lower cure rate and longer TTROD than patients without cancer.

59 tually develop targeted therapies to enhance cure rate and minimize acute and long-term toxic effects

60 ain the delicate balance between high cancer cure rate and overtreatment, which could potentially lea

61 refine current treatment and to improve the cure rate and quality of life of the patients.

62 Newer cancer therapy has increased cancer cure rate and survival time, but such benefit is not ful

63 as proven to have less toxicity and a higher cure rate and therefore, since 1984, has been standard c

64 odern treatment approaches is to improve the cure rate and, at the same time, minimize the long-term

65 els of MDR are driven by case-finding rates, cure rates and amplification probabilities.

66 ased therapy designed to maintain their high cure rates and avoid late effects.

67 treatment-shortening antibiotics to improve cure rates and curb the alarming emergence of drug resis

68 To increase cure rates and decrease long-term toxicity, there is gre

69 arc therapy promise to potentially increase cure rates and decrease toxicity due to increased accura

70 unotherapies promises to further advance the cure rates and improve quality of life of patients.

71 th cavitary TB have the potential to improve cure rates and reduce disease transmission.

72 Dramatic improvements in the cure rates and survival outcomes for children with ALL h

73 therapy offers significantly improved viral cure rates and the possibility of shortened treatment du

74 dihydroartemisinin-piperaquine by increasing cure rates and thereby slowing resistance development.

75 ent of short and safe operations with a high cure rate, and recent studies have not only assessed the

76 providing histopathologic information, high cure rates, and acceptable cosmetic and functional outco

77 of disease and treatment for patients, poor cure rates, and high mortality bring distress to patient

78 For patients with early-stage disease, cure rates approach 100%.

79 ered an easy-to-treat infection, with higher cure rates ( approximately 70%) than other viral genotyp

80 hat will improve the currently disappointing cure rate (approximately 25-40%) of this group of patien

81 th fewer side effects and potentially higher cure rates are currently in development.

82 however, as most tumours are macroadenomas, cure rates are low.

83 HCT for AML, but toxicity remains high, and cure rates are only 25% to 30% for relapsed AML.

84 For those with advanced-stage disease, cure rates are reportedly at least 75%.

85 Cure rate at 3 months after therapy was 70%.

86 rate (65% vs. 44%; P = 0.010) and long-term cure rate at last follow-up (8.8 +/- 0.4 years; range, 0

87 The clinical cure rate at test-of-cure for hospital-acquired cIAI was

88 The overall clinical cure rate at the 30-day visit with the intent-to-treat a

89 The primary efficacy variable was clinical cure rate at the test-of-cure visit (days 25-50).

90 itions for multidrug-resistant tuberculosis, cure rates at 120 weeks were 58% in the bedaquiline grou

91 Using survival analysis, uncorrected patient cure rates at day 28 were 75.7% (95% confidence interval

92 Clinical cure rates at test-of-cure were 80% (146 of 183) for mox

93 trate statistical noninferiority in clinical cure rates at the test-of-cure visit (24-32 days from st

94 The difference in clinical cure rates between the groups was -0.80% (95% CI, -7.1%

95 Definitive chemoradiation results in high cure rates but causes long-term toxicity and may represe

96 addition of other therapies has not enhanced cure rates but identifying patients at greatest risk for

97 e fewest adverse effects and with acceptable cure rates but provided the shortest post-treatment prop

98 n HCV therapeutics have resulted in improved cure rates, but an HCV vaccine is not available and is u

99 Further increase in cure rate can be expected from the discovery of addition

100 High cure rates can be achieved in children with MDR tubercul

101 nt and follow-up protocols mean that overall cure rates can exceed 98% with fertility retention, wher

102 16F10 melanoma model, generating up to a 20% cure rate compared with 0% without AC-NPs.

103 therapy (n = 149) had a significantly higher cure rate compared with patients treated by self-adminis

104 provides superior anatomical and subjective cure rates compared with native tissue repair.

105 Cure rates, complication rates, pathologic findings, len

106 Cure rate (CR) against S. stercoralis was the primary ou

107 Cure rates (CRs) and egg reduction rates (ERRs) were est

108 Polymerase chain reaction (PCR)-adjusted cure rates declined from 100% in 2003 to 81.1% in 2013 a

109 Cure rates did not differ significantly between the two

110 The cure rate difference between the BI and non-BI patients

111 To improve adherence and cure rates, directly observed therapy is recommended for

112 sonably well in most initial studies but its cure rates do not approximate those of open surgery.

113 romise long-term health and to maintain high cure rates, dose-intensive chemotherapy with limited cum

114 DUODX increases the short-term and long-term cure rate due to the detection of more duodenal gastrino

115 tidrug-resistant tuberculosis can yield high cure rates even in resource-poor settings.

116 Although cure rates exceed 80%, considerable unexplained interind

117 e promyelocytic leukemia (APL), resulting in cure rates exceeding 80%.

118 he most common childhood cancer, and despite cure rates exceeding 90% in children, it remains an impo

119 rug Administration approval, with remarkable cure rates exceeding 90%.

120 DAAs became available in January 2014, with cure rates exceeding 90%; only 51 000 veterans in VA car

121 ust our therapeutic approach and improve the cure rate for acute myeloid leukemia with FLT3/ITD.

122 cin began 27 years ago in 1974, changing the cure rate for disseminated disease from 5 to 60%.

123 of lesser chemotherapy to maintain the same cure rate for patients with good-prognosis disease.

124 Suburethral tapes have a higher cure rate for patients with predominant stress urinary i

125 hormone measurement resulted in an excellent cure rate for primary hyperparathyroidism.

126 is not associated with a decreased surgical cure rate for primary hyperparathyroidism.

127 ls for BMT in SCD could greatly increase the cure rate for this devastating disease.

128 s are needed to confirm postulated long-term cure rates for AF.

129 ibiotics have now been shown to decrease the cure rates for anti-C. difficile therapy and increase th

130 Survival and cure rates for childhood cancers in Europe have greatly

131 With steadily improved cure rates for children with newly diagnosed acute lymph

132 Improved cure rates for esophageal and gastric cancer have increa

133 f protease inhibitors that will offer higher cure rates for genotype 1 patients and open the door for

134 that were given for 6 weeks resulted in high cure rates for HCV infection with excellent tolerability

135 We compared serological cure rates for human immunodeficiency virus (HIV)-negati

136 Cure rates for localized high-risk prostate cancers (PCa

137 treatments are needed to accomplish improved cure rates for multidrug-resistant and extensively drug-

138 Clinical and microbiologic cure rates for NGU were somewhat low and there was no si

139 Purpose Improvement of cure rates for patients treated with allogeneic hematopo

140 Cure rates for patients with acute myeloid leukemia (AML

141 ing the hope of increasing the remission and cure rates for patients with acute myeloid leukemia.

142 Despite high cure rates for pediatric B-lineage acute lymphoblastic l

143 Reported cure rates for stress incontinence immediately after a c

144 he trials for CABP (FOCUS 1 and 2), clinical cure rates for the ceftaroline group were numerically hi

145 Cure rates for this rare CNS tumour, which arises mainly

146 g administered orally as a single dose with cure rates for those treated with benzathine penicillin

147 or treatment of hospital-acquired pneumonia, cure rates for those with bacteremic S. aureus pneumonia

148 Miltefosine had demonstrated very good cure rates for visceral leishmaniasis (VL) in India, Nep

149 Microbial cure rates for WC2031 were 95.5% (95% CI, 92.3-98.8) ver

150 -IL-10 antibody pretreatment improved lesion cure rates from 40% to 87% relative to mice pretreated w

151 ormed a logistic meta-regression analysis of cure rates from all falciparum malaria treatment trials

152 leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment.

153 he amount of residual disease should improve cure rates further.

154 ctions, although it is not likely to achieve cure rates >80% in macrolide-resistant strains, in a sim

155 remained the most cost-effective strategy at cure rates >88.4% and CDI recurrence rates <14.9%.

156 However, the pace of increasing the cure rate has slowed over the past 2 decades, and we hav

157 n saved compared with the pre-DOTS era, high cure rates have been achieved in most countries worldwid

158 Hepatitis C virus (HCV) cure rates have been similar in patients with and withou

159 in open urethroplasty with better long-term cure rates have fuelled the continuing debate as to whic

160 from the early days of the 1950s but 5-year cure rates have only barely improved.

161 ral and parenteral therapies achieve similar cure rates; however, oral therapy avoids risks associate

162 s have been refined, resulting in comparable cure rates; however, they all have different side-effect

163 the polymerase-chain-reaction (PCR)-adjusted cure rates (i.e., cure of the original infection; new in

164 The cure rate (ie, polymerase chain reaction-corrected adequ

165 ants [81.7%], respectively; P=0.73), and the cure rate in each active-treatment group was higher than

166 ation with CRCL-loaded DCs resulted in a 75% cure rate in mice with pre-existing 12B1 tumors.

167 A previous study found a high cure rate in Mozambican children with uncomplicated Plas

168 revious controversies including the surgical cure rate in patients with and without Multiple Endocrin

169 Despite a high cure rate in patients with testicular cancer, there rema

170 The cure rate in the artemether-lumefantrine group was signi

171 The cure rate in the conventional remedial group (n = 107) w

172 The high cure rate in this prospective trial with a substantial n

173 -acting antivirals (DAAs) have led to a high cure rate in treated patients with chronic hepatitis C v

174 regimens that might boost the generally low cure rates in adults and subgroups of children with high

175 Cure rates in adults remain low and treatment is complic

176 responses and are thus far unable to affect cure rates in AML patients.

177 Despite these advances, cure rates in AML remain substantially unchanged in rece

178 ogical series of management trials, and high cure rates in both seminomas and non-seminomas have enab

179 Notably, the clinical cure rates in ME patients with methicillin-resistant S.

180 cal radiotherapy and surgery achieve similar cure rates in muscle-invasive bladder cancer, but the ch

181 ndia and has achieved low mortality and high cure rates in nondefaulting children.

182 n procedures (90% and 35%), and hypertension cure rates in patients who underwent revascularization (

183 th the possibility of improving survival and cure rates in patients with breast cancer.

184 urtimox, which have been associated with low cure rates in the chronic stage of the disease and which

185 efloquine-artesunate group; the PCR-adjusted cure rates in the intention-to-treat analysis were 94.2%

186 The PCR-adjusted cure rates in the per-protocol analysis were 94.8% in th

187 important insights into the re-infection and cure rates in the two age groups.

188 SVR12 can be used effectively to determine "cure" rates in trials and in clinical practice.

189 lastic leukemia (ALL) is 80% to 90%, and the cure rate is 40% to 50%.

190 ion therapy of the brain has improved cancer cure rates, learning disorders and memory deficits are a

191 for patients with good-risk GCT, with a high cure rate, low relapse rate, and little evidence of late

192 s with Hodgkin lymphoma, either by improving cure rates, minimizing toxicity, or both.

193 use a variant of survival analysis known as cure rate modelling to differentiate factors that influe

194 an intense regimen of chemotherapy yielding cure rates near 80%.

195 an intense regimen of chemotherapy yielding cure rates near 85%.

196 but maintain the excellent hitherto observed cure rates need to be actively pursued.

197 syngeneic, diabetic recipients resulted in a cure rate of 100% within 5 days.

198 4 months after treatment, producing a final cure rate of 65%.

199 ffective therapy for DL, with a higher final cure rate of 75% observed when used in a total dose abov

200 250 islets overexpressing A20 resulted in a cure rate of 75% with a mean time to cure of 5.2 days, c

201 th 4 obtaining cure, resulting in an overall cure rate of 90%.

202 Surgical resection carries a cure rate of 95% with the use of intraoperative parathyr

203 y invasive techniques (n = 23) resulted in a cure rate of 96% and a mean length of stay of 0.4 +/- 0.

204 compared to conventional exploration with a cure rate of 97.1% and a complication rate of 3.10%.

205 f antimalarial therapy was associated with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.

206 Despite recent advances in the cure rate of acute lymphoblastic leukaemia (ALL), the pr

207 This appears to impact the cure rate of AF patients.

208 In Bihar state, India, the cure rate of antimonial compounds (eg, sodium stibogluco

209 o have a major effect on early death and the cure rate of APL.

210 newly diagnosed lymphomas and has an overall cure rate of approximately 60%.

211 The day 42 cure rate of asexual stages in the DHP + primaquine and

212 Although cure rate of childhood acute lymphoblastic leukemia (ALL

213 netics and pharmacogenetics) have pushed the cure rate of childhood acute lymphoblastic leukemia to n

214 gets is an important strategy to improve the cure rate of diffuse large B-cell lymphoma (DLBCL).

215 Imiquimod leads to an 80-100% cure rate of lentigo maligna; however, studies of invasi

216 ntimalarial potential was revealed by a 100% cure rate of malaria in mice with one administration of

217 ethal gynecologic malignancy with an overall cure rate of merely 30%.

218 lopment of effective treatments has led to a cure rate of more than 80% in children, creating opportu

219 Transplantation of 250 islets resulted in a cure rate of only 20%.

220 varian carcinoma is a deadly disease, with a cure rate of only 30%.

221 The clinical cure rate of patients infected with the epidemic BI C. d

222 have led to a substantial improvement in the cure rate of patients suffering from T-cell acute lympho

223 The cure rate of T. trichiura infection was significantly hi

224 However, the cure rate of these patients is low and the course of the

225 mic BI C. difficile strain is lower than the cure rate of those infected with non-BI strains whether

226 im-sulfamethoxazole yields a higher clinical cure rate of uncomplicated cellulitis than cephalexin al

227 Despite the high cure rate of Wilms tumor, long-term survivors remain at

228 al agents (DAAs), are available that achieve cure rates of >90% in many patient populations including

229 diation before cell transplantation produced cure rates of 14% and 33%, respectively; whereas liver r

230 CI of VEGF121/rGel and PCI of bleomycin with cure rates of 40% and 33% respectively.

231 an antibody directed against CD20, increases cure rates of adults with Burkitt leukemia from 40% to 8

232 s that these RIT approaches will improve the cure rates of allogeneic HCT for the thousands of patien

233 With cure rates of childhood acute lymphoblastic leukemia (AL

234 itial counseling on therapy emphasizes viral cure rates of currently 70%-80% as well as expected side

235 the results were sensitive to changes in the cure rates of HCV therapy, the utility of chronic HCV, t

236 malignancy with current therapy resulting in cure rates of only 60%.

237 There is an imperative need to improve the cure rates of patients diagnosed with invasive bladder c

238 ophils did not significantly change the high cure rates of that regimen but abolished curability in t

239 nevirapine based, was associated with lower cure rates of TV for single-dose therapy.

240 rapy, with or without surgery, are enhancing cure rates, often with preservation of organ function.

241 ure demonstrate no significant difference in cure rates or complications.

242 assignment remained associated with a higher cure rate (P = .04), together with younger age and favor

243 hose patients with good prognostic features, cure rates reach 90% and attempts have been made to redu

244 treatment of gastrointestinal malignancies, cure rates remain low and survival times of patients sho

245 ated with intensive multimodal therapies but cure rates remain suboptimal.

246 Six months after treatment, the final cure rate remained the same in both groups, without any

247 However, new therapies are needed to improve cure rates, shorten treatment duration, and improve tole

248 The comparative cure rate, small amount of drug administered, and tolera

249 was assayed by tumor growth delay and tumor cure rate (TCD(50), radiation dose yielding 50% tumor cu

250 ctomy, multiagent regimens produced a higher cure rate than single-agent therapy (50% vs. 12.5%, =.03

251 re than five drugs can indeed achieve better cure rates than current recommended regimens.

252 habitual exposure to carcinogens have lower cure rates than those that arise from infection with hum

253 f injury to normal tissues limits the cancer cure rates that can be achieved with radiation therapy.

254 isoniazid-resistant tuberculosis had a high cure rate, the cases of recurrence and acquired drug res

255 </= 1.00 mm thickness have a relatively good cure rate, the prognosis for patients with locally advan

256 lts, including fidaxomicin (similar clinical cure rates to vancomycin, with lower recurrence rates fo

257 The unadjusted cure rates, used as a measure of the post-treatment prop

258 ate the real-world ability of achieving high cure rates using patient navigation care models.

259 The cure rate was 100%, as evidenced by normalization of ser

260 The overall cure rate was 13.3%.

261 t 50% reduction of egg excretion and overall cure rate was 47% (IQR, 36%-70%) 6 weeks after the secon

262 The PCR-adjusted cure rate was 57.8% (95% confidence interval [CI], 45.4,

263 ing not responded to treatment, the clinical cure rate was 83% (124/150) for ciprofloxacin compared w

264 The clinical cure rate was 85% after the treatment.

265 months after the end of treatment the final cure rate was 90.3%.

266 The initial cure rate was 95.8% (95% confidence interval [CI], 92.2-

267 The microbiological cure rate was 96% (123/128) for ciprofloxacin compared w

268 At the end of treatment the initial cure rate was 97.5% (intention to treat), and 6 months a

269 r ambulatory, minimally invasive techniques; cure rate was 99%.

270 The cure rate was comparable at day 42 in the ITT population

271 -effect modeling suggested that the enhanced cure rate was greater than what was predicted based on t

272 ferentiated tumor-expressing mutant p53, the cure rate was increased from 30% with irinotecan alone t

273 onfidence interval (CI) of the difference in cure rates was >-10%.

274 Cure rates were 21 of 30 (70%; 95% confidence interval [

275 /mL or lower before reoperation, biochemical cure rates were 44% (59 of 133 patients) and 18% (12 of

276 olled in a pilot study of uncomplicated SAB, cure rates were 88% for telavancin and 89% for standard

277 ESBL-producing Enterobacteriaceae, clinical cure rates were 95.8% (23/24) and 88.5% (23/26) in the c

278 t genotype as non-treatment failures, day 28 cure rates were genotype adjusted to 91.1% (95% CI 84.1-

279 However, 28-day cure rates were low (45.9%), owing to parasite recrudesc

280 with CABP caused by S. pneumoniae, clinical cure rates were markedly higher in the ceftaroline treat

281 Early 'cure rates' were severely limited by their retrospective

282 ing group of patients and resulted in a 100% cure rate when a venous gradient was demonstrated.

283 These agents can achieve very high cure rates when combined with pegylated interferon-beta

284 nd ECOG-PS more than 1 negatively influenced cure rate, which was higher in patients with favorable-r

285 The treatment challenge is to achieve a high cure rate while maintaining long-term renal function.

286 properties and is predicted to give improved cure rates while being recalcitrant to the development o

287 s' tumor are continuing to achieve very good cure rates while lowering long term morbidity for low ri

288 oncologists strive for maintaining excellent cure rates while minimizing toxic effects.

289 The cure rate with albendazole (2.6%) and the egg-reduction

290 The clinical cure rate with ceftazidime-avibactam plus metronidazole

291 The ABC subtype has a approximately 40% cure rate with currently available therapies, which is w

292 o had not been cured with local therapy, the cure rate with systemic antileishmanial agents was 60%.

293 Clinical cure rates with ceftazidime-avibactam plus metronidazole

294 of acute myeloid leukemia therapy, long-term cure rates with chemotherapy alone remain approximately

295 itis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing dema

296 ore treatable diseases and ultimately higher cure rates with less treatment-related morbidities.

297 h IVA, when lesions are not amenable to high cure rates with surgery or radiation (RT).

298 centration >1 microg/mL, however, had higher cure rates with telavancin than with vancomycin.

299 reatment or combining drugs did not increase cure rates with these isolates.

300 Cure rates with this technology are high and complicatio